Completed × Multiple Myeloma × Bendamustine Hydrochloride × Clear all A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Completed
130 enrolled
FT576 in Subjects With Multiple Myeloma
Phase 1 Completed
31 enrolled
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 2 Completed
24 enrolled 13 charts
BEB-2
Phase 2 Completed
120 enrolled 11 charts
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 1/2 Completed
169 enrolled
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Phase 1 Completed
20 enrolled
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Phase 1 Completed
18 enrolled 10 charts
OPTIMAL
Phase 2 Completed
31 enrolled 13 charts
Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Completed
18 enrolled
BVD
Phase 2 Completed
75 enrolled
Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Phase 1/2 Completed
38 enrolled 18 charts
BPV
Phase 2 Completed
46 enrolled
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Phase 1/2 Completed
70 enrolled 11 charts
Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma
Phase 1/2 Completed
57 enrolled 19 charts
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
Phase 1 Completed
20 enrolled
Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM
Phase 2 Completed
30 enrolled
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
Phase 2 Completed
43 enrolled 5 charts
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase 2 Completed
59 enrolled 9 charts
BRd
Phase 2 Completed
50 enrolled
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Phase 2 Completed
60 enrolled
BBD
Phase 2 Completed
79 enrolled
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1/2 Completed
40 enrolled 16 charts